Endologix Releases Positive Results From Study

Endologix said Thursday that interim results from a study comparing its Endologix AFX and AFX2 endovascular abdominal aortic stent grafts to other commercially available competitors demonstrate similar outcomes between the endografts, but that there is a trend towards better performance for AFX/AFX2.

The study began in 2015 and has since included 458 patient, the company said. The primary objective in the study is freedom from aneurysm-related complications. The company said it now plans to follow patients that have been treated for five years.